ClinicalTrials.gg
CompletedNCT03227471Updated Jan 18, 2022Results posted

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

A Phase 1/2 interventional study of IVA and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 38 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-18.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2017, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
8th of 43
225 · median 100
Started
2017
with 2 others
Phase 1/2
2 of 43
none open now
Registered
15th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is one of 2 in phase 1/2, and was the 15th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a first-in-human and proof-of-concept study of VX-445. The study includes 6 parts. Parts A, B, and C were conducted in healthy subjects. Parts D, E, and F were conducted in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or TEZ/IVA (F/MF genotypes).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Parts A, B, and C:

  • Female subjects must be of non-.
  • Between the ages of 18 and 55 years, inclusive.
  • (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight >50 kg

Parts D, E, and F:

  • Body weight ≥35 kg.
  • Subjects must have an eligible CFTR genotype:

    • Parts D and F: Heterozygous for F508del and an MF mutation (F/MF)
    • Part E: Homozygous for F508del (F/F)
  • value ≥40% and ≤90% of predicted mean for age, sex, and height.

Key Exclusion Criteria:

Parts A, B, and C:

  • Any condition possibly affecting drug absorption.
  • History of febrile illness within 14 days before the first study drug dose.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Parts D, E, and F:

  • History of cirrhosis with or without portal hypertension.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • Lung infection with organisms associated with a more rapid decline in pulmonary status.
  • History of solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Placebo comparator
    Part A: Pooled Placebo (Except Cohort A7)

    Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.

    Drug: Matched Placebo

  • Experimental
    Part A: VX-445 (Except Cohort A7)

    Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.

    Drug: VX-445

  • Experimental
    Part A: VX-445 (Cohort A7)

    Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.

    Drug: VX-445

  • Placebo comparator
    Part B: Pooled Placebo (Cohort B1 to B4)

    Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.

    Drug: Matched Placebo

  • Experimental
    Part B: VX-445 (Cohort B1 to B4)

    Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).

    Drug: VX-445

  • Placebo comparator
    Part C: Pooled Placebo (Cohort C1 to C3)

    Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.

    Drug: Matched Placebo

  • Experimental
    Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)

    Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.

    Drug: IVA · Drug: TEZ/IVA · Drug: VX-445

  • Placebo comparator
    Part D: Placebo

    Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.

    Drug: Matched Placebo

  • Experimental
    Part D: VX-445/TEZ/IVA TC - Low Dose

    Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.

    Drug: IVA · Drug: TEZ/IVA · Drug: VX-445

  • Experimental
    Part D: VX-445/TEZ/IVA TC - Medium Dose

    Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.

    Drug: IVA · Drug: TEZ/IVA · Drug: VX-445

  • Experimental
    Part D: VX-445/TEZ/IVA TC - High Dose

    Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.

    Drug: IVA · Drug: TEZ/IVA · Drug: VX-445

  • Active comparator
    Part E: TEZ/IVA

    Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.

    Drug: TEZ/IVA

  • Experimental
    Part E: VX-445/TEZ/IVA TC

    Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.

    Drug: IVA · Drug: TEZ/IVA · Drug: VX-445

  • Placebo comparator
    Part F: Placebo

    Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.

    Drug: Matched Placebo

  • Experimental
    Part F: VX-445/TEZ/VX-561 TC

    Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.

    Drug: VX-445 · Drug: TEZ · Drug: VX-561

Interventions

  • DrugIVA

    IVA tablet for oral administration

    Also known as: VX-770, ivacaftor

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    TEZ/IVA fixed-dose combination for oral administration.

    Also known as: VX-661/VX-770, tezacaftor/ivacaftor

  • DrugVX-445

    VX-445 tablet for oral administration.

    Also known as: ELX, elexacaftor

  • DrugMatched Placebo

    Matched placebo.

  • DrugTEZ

    Tablet for oral administration.

    Also known as: VX-661, tezacaftor

  • DrugVX-561

    Tablet for oral administration.

    Also known as: CTP-656

  • DrugVX-445

    VX-445 IV injection

    Also known as: ELX, elexacaftor

06

What researchers measure

Primary outcomes

  1. Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of study drug in treatment period up to safety follow-up (up to 28 days)

  2. Parts D, E and F: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks)

  3. Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  4. Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  5. Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

Secondary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of VX-445

    Time frame: Cohort A1-A5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose

  2. Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445

    Time frame: Cohort A1-5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose

  3. Part B: Maximum Observed Concentration (Cmax) of VX-445

    Time frame: Pre-dose to 96 hours post-dose on Day 1 and Day 10

  4. Part B: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445

    Time frame: Pre-dose to 96 hours post-dose on Day 1 and Day 10

  5. Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445

    Time frame: Pre-dose on Day 10

  6. Part C: Maximum Observed Concentration (Cmax) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

    Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

  7. Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

    Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

  8. Part C: Maximum Observed Concentration (Cmax) of IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

  9. Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14

  10. Part C: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)

    Time frame: Pre-dose on Day 7 and Day 14

  11. Part C: Observed Pre-dose Concentration (Ctrough) of IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose on Day 7 and Day 14

  12. Part D: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ), IVA and Its Metabolite (M1-IVA)

    Time frame: Pre-dose on Day 15 and Day 29

  13. Part E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)

    Time frame: Pre-dose on Day 15 and Day 29

  14. Part F: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and VX-561

    Time frame: Pre-dose on Day 15 and Day 29

  15. Part D: Absolute Change in Sweat Chloride Concentration

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Day 29

  16. Part E: Absolute Change in Sweat Chloride Concentration

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Day 29

  17. Part F: Absolute Change in Sweat Chloride Concentration

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Day 29

  18. Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  19. Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  20. Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  21. Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline through Day 29

  22. Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline through Day 29

  23. Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline through Day 29

07

Results

Posted Jan 18, 2022

Participant flow

Participant flow — Overall Study
MilestonePart A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Started930872561712102221721822
Safety set930872561712102221721821
Completed930872461712102221720821
Not completed000010000000101
Withdrew: Withdrawal by subject000010000000100
Withdrew: Randomized, never dosed000000000000001

Outcome measures

PrimaryParts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose of study drug in treatment period up to safety follow-up (up to 28 days)
Reported as:
Count of participants · Participants
Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)
Participants with AEs0312225
Participants with SAEs0000000
PrimaryParts D, E and F: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks)
Reported as:
Count of participants · Participants
Parts D, E and F: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart D: PlaceboPart D: VX-445/TEZ/IVA TCPart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Participants with AEs1249519719
Participants with SAEs231010
PrimaryPart D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percentage points
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High Dose
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)0.0 ± 2.011.1 ± 2.17.9 ± 1.413.8 ± 1.4
Statistical analysis
  • Part D: Placebo · Mixed-effects model for repeated measure · p = 0.9943 (P value within treatment)
  • Part D: VX-445/TEZ/IVA TC - Low Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment)
  • Part D: VX-445/TEZ/IVA TC - Medium Dose · Mixed-effects model for repeated measure · p = < 0.0001 (P value within treatment)
  • Part D: VX-445/TEZ/IVA TC - High Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment)
PrimaryPart E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percentage points
Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart E: TEZ/IVAPart E: VX-445/TEZ/IVA TC
Part E: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)0.4 ± 2.811.0 ± 1.5
Statistical analysis
  • Part E: TEZ/IVA · Mixed-effects model for repeated measure · p = 0.8869 (P value within treatment.)
  • Part E: VX-445/TEZ/IVA TC · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment)
PrimaryPart F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percentage points
Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Part F: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)1.2 ± 2.611.7 ± 1.6
Statistical analysis
  • Part F: Placebo · Mixed-effects model for repeated measure · p = 0.6407 (P value within treatment)
  • Part F: VX-445/TEZ/VX-561 TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment.)
SecondaryPart A: Maximum Observed Concentration (Cmax) of VX-445
Time frame:
Cohort A1-A5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose
Reported as:
Geometric mean · microgram per milliliter
Part A: Maximum Observed Concentration (Cmax) of VX-445
microgram per milliliterPart A: VX-445 (Cohort A1)Part A: VX-445 (Cohort A2)Part A: VX-445 (Cohort A3)Part A: VX-445 (Cohort A4)Part A: VX-445 (Cohort A5)Part A: VX-445 (Cohort A7-Fasted)Part A: VX-445 (Cohort A7-Fed)Part A: VX-445 (Cohort A7-IV)
Part A: Maximum Observed Concentration (Cmax) of VX-4450.398 ± 23.00.989 ± 35.12.52 ± 13.04.56 ± 28.27.07 ± 19.10.486 ± 27.41.76 ± 14.60.740 ± 27.1
SecondaryPart A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
Time frame:
Cohort A1-5: Pre-dose to 96 hours post-dose; Cohort A7: Pre-dose to 120 hours post-dose
Reported as:
Geometric mean · microgram*hour per milliliter
Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
microgram*hour per milliliterPart A: VX-445 (Cohort A1)Part A: VX-445 (Cohort A2)Part A: VX-445 (Cohort A3)Part A: VX-445 (Cohort A4)Part A: VX-445 (Cohort A5)Part A: VX-445 (Cohort A7-Fasted)Part A: VX-445 (Cohort A7-Fed)Part A: VX-445 (Cohort A7-IV)
Part A: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-44511.4 ± 34.230.8 ± 21.287.1 ± 39.9125 ± 34.2286 ± 9.3021.8 ± 31.555.1 ± 14.913.6 ± 19.7
SecondaryPart B: Maximum Observed Concentration (Cmax) of VX-445
Time frame:
Pre-dose to 96 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · microgram per milliliter
Part B: Maximum Observed Concentration (Cmax) of VX-445
microgram per milliliterPart B: VX-445 (Cohort B1)Part B: VX-445 (Cohort B2)Part B: VX-445 (Cohort B3)Part B: VX-445 (Cohort B4)
Day 11.18 ± 19.92.82 ± 25.53.47 ± 52.99.56 ± 65.6
Day 102.13 ± 155.83 ± 28.111.4 ± 27.218.2 ± 29.5
SecondaryPart B: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
Time frame:
Pre-dose to 96 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · microgram*hour per milliliter
Part B: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445
microgram*hour per milliliterPart B: VX-445 (Cohort B1)Part B: VX-445 (Cohort B2)Part B: VX-445 (Cohort B3)Part B: VX-445 (Cohort B4)
Day 117.9 ± 20.042.2 ± 19.557.9 ± 42.8119 ± 27.5
Day 1061.4 ± 21.8183 ± 32.7452 ± 41.5692 ± 47.6
SecondaryPart B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445
Time frame:
Pre-dose on Day 10
Reported as:
Geometric mean · microgram per milliliter
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445
microgram per milliliterPart B: VX-445 (Cohort B1)Part B: VX-445 (Cohort B2)Part B: VX-445 (Cohort B3)Part B: VX-445 (Cohort B4)
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-4451.05 ± 24.52.81 ± 33.27.10 ± 30.111.5 ± 32.0
SecondaryPart C: Maximum Observed Concentration (Cmax) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame:
Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Reported as:
Geometric mean · microgram per milliliter
Part C: Maximum Observed Concentration (Cmax) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
microgram per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
VX-445: Day 13.04 ± 23.24.86 ± 25.41.72 ± 16.5
VX-445: Day 78.29 ± 31.910.3 ± 18.43.58 ± 14.8
VX-445: Day 148.71 ± 9.6514.0 ± 19.24.73 ± 15.9
TEZ: Day 13.81 ± 16.45.67 ± 17.25.38 ± 19.2
TEZ: Day 77.09 ± 19.48.29 ± 13.67.01 ± 14.7
TEZ: Day 148.11 ± 21.29.07 ± 7.608.60 ± 12.8
M1-TEZ: Day 10.929 ± 350.988 ± 31.71.30 ± 17.3
M1-TEZ: Day 74.34 ± 28.75.19 ± 16.85.86 ± 11.3
M1-TEZ: Day 145.77 ± 24.66.79 ± 14.97.54 ± 11.8
M2-TEZ: Day 10.553 ± 47.00.667 ± 39.60.716 ± 17.0
M2-TEZ: Day 74.72 ± 30.36.41 ± 33.25.46 ± 29.4
M2-TEZ: Day 147.69 ± 23.710.1 ± 24.27.93 ± 28.3
SecondaryPart C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame:
Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Reported as:
Geometric mean · microgram*hour per milliliter
Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
microgram*hour per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
VX-445: Day 148.6 ± 22.772.5 ± 20.726.4 ± 13.8
VX-445: Day 7156 ± 37.1177 ± 30.065.4 ± 20.7
VX-445: Day 14345 ± 30.7506 ± 31.5183 ± 18.8
TEZ: Day 141.4 ± 27.543.8 ± 9.9142.7 ± 20.9
TEZ: Day 7103 ± 35.8105 ± 16.596.9 ± 18.9
TEZ: Day 14252 ± 35.1288 ± 13.6275 ± 19.5
M1-TEZ: Day 117.7 ± 37.220.1 ± 35.225.5 ± 19.1
M1-TEZ: Day 790.9 ± 29.9110 ± 17.8125 ± 14.1
M1-TEZ: Day 14380 ± 22.1477 ± 16.0512 ± 17.9
M2-TEZ: Day 16.65 ± 48.68.19 ± 52.59.00 ± 16.6
M2-TEZ: Day 7108 ± 31.2143 ± 34.1123 ± 28.7
M2-TEZ: Day 14617 ± 23.2831 ± 29.5652 ± 31.2
SecondaryPart C: Maximum Observed Concentration (Cmax) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Reported as:
Geometric mean · nanogram per milliliter
Part C: Maximum Observed Concentration (Cmax) of IVA and Its Metabolites (M1-IVA and M6-IVA)
nanogram per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
IVA: Day 1425 ± 29.8461 ± 49.3437 ± 9.63
IVA: Day 71290 ± 41.11190 ± 42.41070 ± 20.0
IVA: Day 141360 ± 21.91920 ± 33.71410 ± 25.5
M1-IVA: Day 11250 ± 29.91190 ± 28.11070 ± 28.6
M1-IVA: Day 72460 ± 26.82590 ± 28.12070 ± 23.1
M1-IVA: Day 142680 ± 19.43900 ± 21.42990 ± 28.3
M6-IVA: Day 1901 ± 38.21180 ± 16.6631 ± 31.1
M6-IVA: Day 71960 ± 38.12590 ± 7.31400 ± 29.8
M6-IVA: Day 142060 ± 30.13350 ± 17.41980 ± 34.7
SecondaryPart C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose to 96 hours post-dose on Day 1, Day 7 and Day 14
Reported as:
Geometric mean · nanogram*hour per milliliter
Part C: Area Under Plasma Concentration Time Curve From Time of Dosing to Last Measurable Concentration (AUC0-tlast) of IVA and Its Metabolites (M1-IVA and M6-IVA)
nanogram*hour per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
IVA: Day 16350 ± 40.96210 ± 45.55480 ± 28.5
IVA: Day 721600 ± 65.618800 ± 50.716900 ± 28.4
IVA: Day 1427900 ± 48.735000 ± 44.832600 ± 40.6
M1-IVA: Day 116900 ± 38.914800 ± 32.313300 ± 21.1
M1-IVA: Day 747500 ± 43.646300 ± 30.636400 ± 25.9
M1-IVA: Day 1475300 ± 42.797000 ± 31.386100 ± 30.2
M6-IVA: Day 111100 ± 49.914100 ± 20.39050 ± 26.1
M6-IVA: Day 739700 ± 38.851400 ± 13.029100 ± 36.0
M6-IVA: Day 1466300 ± 44.9123000 ± 23.167100 ± 42.3
SecondaryPart C: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
Time frame:
Pre-dose on Day 7 and Day 14
Reported as:
Geometric mean · microgram per milliliter
Part C: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolites (M1-TEZ and M2-TEZ)
microgram per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
VX-445: Day 74.63 ± 46.85.91 ± 35.52.09 ± 14.9
VX-445: Day 144.45 ± 38.97.60 ± 29.82.92 ± 13.2
TEZ: Day 72.73 ± 48.72.77 ± 19.22.52 ± 23.0
TEZ: Day 143.10 ± 33.43.70 ± 16.03.62 ± 24.6
M1-TEZ: Day 73.36 ± 27.13.98 ± 16.84.71 ± 14.0
M1-TEZ: Day 144.38 ± 20.55.42 ± 16.15.52 ± 12.9
M2-TEZ: Day 74.06 ± 32.85.63 ± 37.54.92 ± 27.7
M2-TEZ: Day 146.46 ± 22.58.85 ± 29.97.38 ± 29.6
SecondaryPart C: Observed Pre-dose Concentration (Ctrough) of IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose on Day 7 and Day 14
Reported as:
Geometric mean · nanogram per milliliter
Part C: Observed Pre-dose Concentration (Ctrough) of IVA and Its Metabolites (M1-IVA and M6-IVA)
nanogram per milliliterPart C: VX-445/TEZ/IVA TC (Cohort C1)Part C: VX-445/TEZ/IVA TC (Cohort C2)Part C: VX-445/TEZ/IVA TC (Cohort C3)
IVA: Day 7753 ± 75759 ± 45.7604 ± 32.8
IVA: Day 14610 ± 55.6990 ± 43.4881 ± 35.3
M1-IVA: Day 71790 ± 43.71960 ± 21.41400 ± 21.3
M1-IVA: Day 141600 ± 46.22210 ± 19.81930 ± 16.9
M6-IVA: Day 71530 ± 31.52260 ± 11.91270 ± 32.1
M6-IVA: Day 141360 ± 49.12600 ± 18.01640 ± 27.0
SecondaryPart D: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ), IVA and Its Metabolite (M1-IVA)
Time frame:
Pre-dose on Day 15 and Day 29
Reported as:
Mean · microgram per milliliter
Part D: Observed Pre-dose Plasma Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ), IVA and Its Metabolite (M1-IVA)
microgram per milliliterPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High Dose
VX-445: Day 151.04 ± 0.6122.15 ± 0.9775.77 ± 4.14
VX-445: Day 291.27 ± 0.5302.18 ± 1.265.57 ± 2.80
TEZ: Day 151.85 ± 1.261.68 ± 0.7001.76 ± 0.960
TEZ: Day 292.16 ± 1.271.77 ± 0.8332.22 ± 1.62
M1-TEZ: Day 154.46 ± 1.964.11 ± 1.474.43 ± 1.79
M1-TEZ: Day 294.77 ± 2.044.30 ± 1.554.74 ± 1.89
IVA: Day 150.720 ± 0.4840.665 ± 0.4140.701 ± 0.593
IVA: Day 290.753 ± 0.4240.704 ± 0.4140.658 ± 0.386
M1-IVA: Day 151.29 ± 0.7481.21 ± 0.6661.45 ± 1.22
M1-IVA: Day 291.57 ± 0.8301.20 ± 0.7171.29 ± 0.797
SecondaryPart E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)
Time frame:
Pre-dose on Day 15 and Day 29
Reported as:
Mean · microgram per milliliter
Part E: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and IVA and Its Metabolite (M1-IVA)
microgram per milliliterPart E: TEZ/IVAPart E: VX-445/TEZ/IVA TC
VX-445: Day 15—5.07 ± 2.47
VX-445: Day 29—5.35 ± 3.73
TEZ: Day 151.85 ± 0.8631.86 ± 1.09
TEZ: Day 291.84 ± 1.281.99 ± 1.55
M1-TEZ: Day 153.96 ± 1.764.57 ± 1.73
M1-TEZ: Day 293.73 ± 1.514.71 ± 1.86
IVA: Day 150.766 ± 0.3660.659 ± 0.529
IVA: Day 290.595 ± 0.3030.798 ± 0.901
M1-IVA: Day 151.22 ± 0.4701.09 ± 0.973
M1-IVA: Day 290.943 ± 0.4311.43 ± 1.54
SecondaryPart F: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and VX-561
Time frame:
Pre-dose on Day 15 and Day 29
Reported as:
Mean · microgram per milliliter
Part F: Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ and Its Metabolite (M1-TEZ) and VX-561
microgram per milliliterPart F: VX-445/TEZ/VX-561 TC
VX-445: Day 154.40 ± 1.54
VX-445: Day 295.25 ± 2.88
TEZ: Day 151.80 ± 0.658
TEZ: Day 292.22 ± 1.65
M1-TEZ: Day 154.99 ± 1.71
M1-TEZ: Day 295.09 ± 1.37
VX-561: Day 150.441 ± 0.174
VX-561: Day 290.597 ± 0.473
SecondaryPart D: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part D: Absolute Change in Sweat Chloride Concentration
millimole per liter (mmol/L)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High Dose
Part D: Absolute Change in Sweat Chloride Concentration-2.2 ± 3.9-38.2 ± 4.2-33.2 ± 2.8-39.1 ± 2.9
Statistical analysis
  • Part D: Placebo · Mixed-effects model for repeated measure · p = 0.5802 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Low Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Medium Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - High Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart E: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · mmol/L
Part E: Absolute Change in Sweat Chloride Concentration
mmol/LPart E: TEZ/IVAPart E: VX-445/TEZ/IVA TC
Part E: Absolute Change in Sweat Chloride Concentration0.8 ± 4.9-39.6 ± 2.8
Statistical analysis
  • Part E: TEZ/IVA · mixed-effects model for repeated measure · p = 0.8712 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part E: VX-445/TEZ/IVA TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart F: Absolute Change in Sweat Chloride Concentration

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · mmol/L
Part F: Absolute Change in Sweat Chloride Concentration
mmol/LPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Part F: Absolute Change in Sweat Chloride Concentration1.0 ± 4.6-33.6 ± 2.8
Statistical analysis
  • Part F: Placebo · mixed-effects model for repeated measure · p = 0.8359 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part F: VX-445/TEZ/VX-561 TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percent change
Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent changePart D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High Dose
Part D: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)0.3 ± 4.019.3 ± 4.213.8 ± 2.826.2 ± 2.9
Statistical analysis
  • Part D: Placebo · Mixed-effects model for repeated measure · p = 0.9453 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Low Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Medium Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - High Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percent change
Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent changePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TC
Part E: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)1.4 ± 5.019.2 ± 2.7
Statistical analysis
  • Part E: TEZ/IVA · mixed-effects model for repeated measure · p = 0.7849 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part E: VX-445/TEZ/IVA TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percent change
Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent changePart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Part F: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)1.6 ± 4.619.9 ± 2.8
Statistical analysis
  • Part F: Placebo · mixed-effects model for repeated measure · p = 0.7356 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part F: VX-445/TEZ/VX-561 TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · units on a scale
Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scalePart D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High Dose
Part D: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score4.2 ± 4.920.8 ± 5.415.4 ± 3.725.7 ± 3.7
Statistical analysis
  • Part D: Placebo · Mixed-effects model for repeated measure · p = 0.3940 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Low Dose · Mixed-effects model for repeated measure · p = 0.0003 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - Medium Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part D: VX-445/TEZ/IVA TC - High Dose · Mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · units on a scale
Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scalePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TC
Part E: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score5.2 ± 7.120.7 ± 4.0
Statistical analysis
  • Part E: TEZ/IVA · mixed-effects model for repeated measure · p = 0.4757 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part E: VX-445/TEZ/IVA TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)
SecondaryPart F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · units on a scale
Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scalePart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Part F: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score20.2 ± 6.920.2 ± 4.3
Statistical analysis
  • Part F: Placebo · mixed-effects model for repeated measure · p = 0.0070 (P value within treatment. These are nominal p-values without multiplicity control.)
  • Part F: VX-445/TEZ/VX-561 TC · mixed-effects model for repeated measure · p = <0.0001 (P value within treatment. These are nominal p-values without multiplicity control.)

Adverse events

Collected over Parts A, B and C: From first dose of study drug in treatment period up to safety follow-up (up to 28 days); Parts D, E and F: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug (up to 5 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Pooled Placebo (Except Cohort A7)0/9 (0%)0/9 (0%)0/9 (0%)
Part A: VX-445 (Except Cohort A7)0/30 (0%)0/30 (0%)3/30 (10%)
Part A: VX-445 (Cohort A7)0/8 (0%)0/8 (0%)1/8 (12.5%)
Part B: Pooled Placebo (Cohort B1 to B4)0/7 (0%)0/7 (0%)2/7 (28.6%)
Part B: VX-445 (Cohort B1 to B4)0/25 (0%)0/25 (0%)2/25 (8%)
Part C: Pooled Placebo (Cohort C1 to C3)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)0/17 (0%)0/17 (0%)5/17 (29.4%)
Part D: Placebo0/12 (0%)2/12 (16.7%)12/12 (100%)
Part D: VX-445/TEZ/IVA TC - Low Dose0/10 (0%)1/10 (10%)10/10 (100%)
Part D: VX-445/TEZ/IVA TC - Medium Dose0/22 (0%)2/22 (9.1%)19/22 (86.4%)
Part D: VX-445/TEZ/IVA TC - High Dose0/21 (0%)0/21 (0%)17/21 (81%)
Part E: TEZ/IVA0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Part E: VX-445/TEZ/IVA TC0/21 (0%)0/21 (0%)18/21 (85.7%)
Part F: Placebo0/8 (0%)1/8 (12.5%)7/8 (87.5%)
Part F: VX-445/TEZ/VX-561 TC0/21 (0%)0/21 (0%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventPart A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/90/300/80/70/250/60/171/121/102/220/211/70/211/80/21
Distal intestinal obstruction syndromeGastrointestinal disorders0/90/300/80/70/250/60/170/121/100/220/210/70/210/80/21
Jugular vein thrombosisRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/60/170/121/100/220/210/70/210/80/21
HaemoptysisRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/60/171/120/100/220/210/70/210/80/21
Influenza A virus test positiveInvestigations0/90/300/80/70/250/60/170/120/101/220/210/70/210/80/21
Most frequent other events
Showing 10 of 80
Most frequent other events
EventPart A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TC
CoughRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/61/171/124/105/227/211/77/212/85/21
Sputum increasedRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/60/173/123/104/225/210/78/211/83/21
NauseaGastrointestinal disorders0/91/300/80/70/251/60/172/122/103/221/211/71/213/82/21
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/90/300/80/70/250/60/174/122/104/222/210/75/213/83/21
FatigueGeneral disorders0/90/300/80/70/250/61/174/121/100/220/210/74/210/80/21
VomitingGastrointestinal disorders0/90/300/80/70/250/61/170/120/101/221/211/70/212/80/21
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/60/172/122/102/222/211/71/212/85/21
HaemoptysisRespiratory, thoracic and mediastinal disorders0/90/300/80/70/250/60/172/120/105/222/210/73/211/81/21
PyrexiaGeneral disorders0/90/300/80/70/250/60/171/120/105/221/211/73/210/80/21
HeadacheNervous system disorders0/90/300/80/71/250/62/172/122/102/222/211/70/211/81/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TCTotal
<=18 years0000000000000000
Between 18 and 65 years930872561712102221721821224
>=65 years0000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TCTotal
Female2200300267111951058
Male72887226171041510612311166
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TCTotal
Hispanic or Latino02201150001010013
Not Hispanic or Latino928672451212102220720820210
Unknown or Not Reported0000000000000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Pooled Placebo (Except Cohort A7)Part A: VX-445 (Except Cohort A7)Part A: VX-445 (Cohort A7)Part B: Pooled Placebo (Cohort B1 to B4)Part B: VX-445 (Cohort B1 to B4)Part C: Pooled Placebo (Cohort C1 to C3)Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)Part D: PlaceboPart D: VX-445/TEZ/IVA TC - Low DosePart D: VX-445/TEZ/IVA TC - Medium DosePart D: VX-445/TEZ/IVA TC - High DosePart E: TEZ/IVAPart E: VX-445/TEZ/IVA TCPart F: PlaceboPart F: VX-445/TEZ/VX-561 TCTotal
American Indian or Alaska Native0000000000000000
Asian0002000000000002
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American416439410100000042
White51442162161282221721820178
More than one race0000000000000000
Unknown or Not Reported0000000010000012
08

Study locations

38 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Valley Children's Healthcare
    Madera, California 93636, United States
  • (Kaiser Permanente) Oakland Medical Center
    Oakland, California 96411, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Tampa General Hospital Cardiac and Lung Transplant Clinic
    Tampa, Florida 33606, United States
  • Children's Specialty Services at North Druid Hills
    Atlanta, Georgia 30324, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Covance Clinical Research Unit Inc., Evansville Clinic [Parts A, B, C only]
    Evansville, Indiana 47710, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Harper University Hospital
    Detroit, Michigan 48201, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minn
    Minneapolis, Minnesota 55404, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • University of New Mexico School of Medicine
    Albuquerque, New Mexico 87131, United States
  • UC Health Office of Clinical Research
    Cincinnati, Ohio 45267, United States
  • University Hospitals Cleveland Medical Center/Rainbow Babies and Children's Hospital
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Austin Children's Chest Associates
    Austin, Texas 78723, United States
  • The University of Vermont
    Burlington, Vermont 05401, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • West Virginia University Hospitals
    Morgantown, Virginia 26506, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Monash Medical Center
    Clayton, Victoria, Australia
  • The Alfred Hospital
    Melbourne, Victoria, Australia
  • The Royal Children's Hospital Melbourne
    Parkville, Victoria, Australia
  • Mater Adult Hospital
    Brisbane, Australia
  • Royal Prince Alfred Hospital
    Sydney, Australia
  • Westmead Hospital
    Sydney, Australia
  • Antwerp University Hospital
    Edegem, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • Academic Medical Centre
    Amsterdam, Netherlands
  • HagaZiekenhuis van den Haag
    Den Haag, Netherlands
  • Radboud UMC
    Nijmegen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18. PubMed 30334692 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Mar 2018, 14 months.

Results were first posted in Jan 2022, 3 years 9 months after primary completion. A results delay was requested in Mar 2019.

Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2017
First posted
Jul 24, 2017
StartActual
Jan 23, 2017
Primary completionActual
Mar 27, 2018
CompletionActual
Mar 27, 2018
Results delay requested
Mar 26, 2019
Results first posted
Jan 18, 2022
Last update
Jan 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03227471
Responsible party
Sponsor
First posted
Jul 24, 2017
Start date
Jan 23, 2017
Primary completion
Mar 27, 2018
Completion
Mar 27, 2018
Results posted
Jan 18, 2022
Last update
Jan 18, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor · Elexacaftor

Start the discussion